Supplementary materials: Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma

These are peer-reviewed supplementary materials for the article 'Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma' published in the Journal of Comparative Effectiveness Research.

• Supplementary Figure 1: Flow chart of patient selection in real-world SoC cohort
• Supplementary Table 1: Baseline characteristics for ELARA cohort and real-world SoC cohort before and after weighting, subpopulation for evaluating CRR/ORR.
• Supplementary Table 2: Efficacy comparison between ELARA cohort and real-world SoC cohort from sensitivity analyses.

Aim: To contextualize the effectiveness of tisagenlecleucel versus real-world standard of care (SoC) in relapsed/refractory follicular lymphoma. Materials & methods: A retrospective indirect matched comparison study using data from the phase II ELARA trial and the US Flatiron Health Research Database. Results: Complete response rate was 69.1 versus 17.7% and the overall response rate was 85.6 versus 58.1% in tisagenlecleucel versus SoC, post weighting by odds. For overall survival, an estimated reduction in the risk of death was observed in favor of tisagenlecleucel over SoC. The hazard ratio for progression free survival was 0.45 (95% CI: 0.26, 0.88), and for time-to-next treatment was 0.34 (95% CI: 0.15, 0.78) with tisagenlecleucel versus SoC. Conclusion: A consistent trend toward improved efficacy end points was observed in favor of tisagenlecleucel versus SoC.